Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Centivax
AddedFeb 15, 2024
UpdatedJun 18, 2026
Centivax

Centivax

Seed

Centivax: A healthcare agency offering biotech, pharma, medical device manufacturing & therapeutics.

HQ
South San Francisco, CA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Centivax, founded with a mission to accelerate the world’s transition to a post-pathogen humanity, is a healthcare agency specializing in biotechnology, pharmaceuticals, medical device manufacturing, and therapeutics. The company focuses on developing broad-spectrum vaccines, with its first vaccine aimed at preventing all influenza currently in pre-clinical development in ferrets and pigs.

Notable individuals affiliated with Centivax include experts in biotechnology and pharmaceuticals, though specific names are not provided. The company has achieved significant milestones in its vaccine development efforts, positioning itself as a key player in the fight against infectious diseases. Centivax's impact lies in its innovative approach to creating broad-spectrum vaccines, potentially revolutionizing how humanity combats pathogens.

Centivax - Similar Companies

Pathovax logo

Pathovax

pathovax.com

Vaxxinity logo

Vaxxinity

vaxxinity.com

X-Vax Technology logo

X-Vax Technology

InvVax logo

InvVax

inv-vax.com

Agilvax logo

Agilvax

PaxVax logo

PaxVax

VitriVax logo

VitriVax

vitrivaxbio.com

VaxCare logo

VaxCare

vaxcare.com

Cancervax logo

Cancervax

cancervax.com

Vaxform logo

Vaxform

vaxform.com

Novavax logo

Novavax

novavax.com

Genvax Technologies logo

Genvax Technologies

Vaxent logo

Vaxent

FruitVaccine logo

FruitVaccine

fruitvaccine.org

Coalition for Epidemic Preparedness Innovations logo

Coalition for Epidemic Preparedness Innovations

cepi.net

Centivax - Quick Facts

Who are Centivax's competitors?

Companies similar to Centivax include Pathovax, Vaxxinity, X-Vax Technology and InvVax.

When was Centivax founded?

Centivax was founded in 2020.

Where is Centivax's headquarters located?

Centivax's headquarters is located in South San Francisco, CA, US.

When was Centivax's last funding round?

Centivax's most recent funding round was for $10M (USD) in November 2022.

How much has Centivax raised to-date?

As of Nov 16, 2022, Centivax has raised a total of $14.2M (USD).

How many employees does Centivax have?

Centivax has 20 employees as of Feb 4, 2024.

Centivax - Classification

Industry
  • Professional Service Companies
Technology
  • Biotech
Geographic Exposure
  • Global
Customer
  • Enterprise
Main Product
  • Therapeutics
  • Vaccines
Tags
  • Consulting
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified